AIM ImmunoTech CEO buys 22,000 shares at $0.221
AIM ImmunoTech Inc. (AIM) reported that CEO & President Thomas K. Equels purchased 22,000 shares of its Common Stock on September 15, 2026 in a purchase described as an open market or private transaction at $0.221 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AIM ImmunoTech Inc. (AIM) reported that CEO & President Thomas K. Equels purchased 22,000 shares of its Common Stock on September 15, 2026 in a purchase described as an open market or private transaction at $0.221 per share. Following this buy, he directly owns 91,822 shares of AIM Common Stock. No Rule 10b5-1 trading plan is reported for this transaction.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 22,000 | $0.221 | $5K |
Key Figures
Key Terms
Common Stock financial
open market or private transaction financial
Rule 10b5-1 regulatory
directly owns financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did AIM ImmunoTech (AIM) disclose in this Form 4?
Was the AIM ImmunoTech (AIM) CEO’s stock purchase under a Rule 10b5-1 plan?
What type of security did the AIM (AIM ImmunoTech) insider acquire?
AI-generated analysis. How Rhea-AI works. Not financial advice.